Press Releases
GT Biopharma Announces Updated Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE™ Trial an Investigational Immunotherapy for Refractory Cancers to be Presented at ESMO Congress 2021
GT Biopharma Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies
GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform Technologies
GT Biopharma to Present at Upcoming September Investor Conferences
GT Biopharma Announces the Promotion of Dr. Gregory Berk to President of Research & Development and Chief Medical Officer
GT Biopharma Provides Second Quarter 2021 Business Update
GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results
GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™
GT Biopharma Announces $16 million in Warrant Exercise Proceeds
